Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia
Bibliographic Data
| ID | 14909326 |
|---|---|
| Authors | Jenny Iversen (0000-0002-0062-7300, UNSW Sydney, corresponding author), J Grebely (0000-0002-1833-2017, UNSW Sydney), Beth Catlett (0000-0003-3803-5391, St Vincents Institute of Medical Research), Philip Cunningham (0000-0003-2613-6910, St Vincents Institute of Medical Research), Gregory J Dore (0000-0002-4741-2622, UNSW Sydney), Lisa Maher (0000-0001-6020-6519, UNSW Sydney) |
| Year | 2017 |
| Volume | 47 |
| Pages | 77-85 |
| Publication date | 2017-09-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | International Journal of Drug Policy (JOURNAL) |
| Journal identifiers | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2017.05.022 |
| PMID | 28578863 |
| OpenAlex | W2620924543 |
| Language | EN |
| Citations received | 22 |
| References cited | 42 |
Antibody · Hepatitis C · Hepatitis C virus · Virus · Hepatitis C virus research · HIV, Drug Use, Sexual Risk · HIV/AIDS Research and Interventions · Medicine · Emergency Medicine · Immunology · Internal Medicine · Virology
Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations
On-site testing and case management to improve hepatitis C care in drug users
Point-of-care hepatitis C testing from needle and syringe programs
Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia
Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia
Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs
Effectiveness of periodic incentives on clinic attendance and hepatitis C testing and treatment for people who inject drugs
Elimination of hepatitis C virus infection among PWID
Has the HCV cascade of care changed among people who inject drugs in England since the introduction of direct-acting antivirals
The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia
Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India
Elimination of hepatitis C virus infection among people who use drugs
Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia
Individual and network factors associated with HCV treatment uptake among people who inject drugs
Conceptualising access in the direct-acting antiviral era
Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland
Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility
Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs
Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs
Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs
Beyond a ‘post-cure’ world
Achievement of hepatitis C cascade of care milestones
The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs
Hepatitis C virus treatment for prevention among people who inject drugs
Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics
Reduction in HCV Incidence Among Injection Drug Users Attending Needle and Syringe Programs in Australia
Staying Safe From Hepatitis C
| Unique citing works | 22 |
|---|---|
| Citations per year | 2,44 |
| Citation span | 2017 - 2025 (9) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 22 |